Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,022.21 -29.20 (-0.58%) Dow
37,753.31 -45.66 (-0.12%) Nasdaq
15,683.37 -181.88 (-1.15%) Bitcoin USD
62,690.39 -364.41 (-0.58%) CMC Crypto 200
885.54 0.00 (0.00%)
LLY Jan 2025 270.000 put
| Previous close | 0.7000 |
| Open | 0.7000 |
| Bid | 0.0000 |
| Ask | 3.2000 |
| Strike | 270.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.7000 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 65 |
- Yahoo Finance Video
Eli Lilly's weight loss drug could help sleep apnea patients
Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep. The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Angel Smith
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo
Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.
ZacksTop Research Reports for Eli Lilly, Linde & Caterpillar
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT).
